These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 28749961)

  • 1. Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer.
    Makondi PT; Chu CM; Wei PL; Chang YJ
    PLoS One; 2017; 12(7):e0180616. PubMed ID: 28749961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening key genes and signaling pathways in colorectal cancer by integrated bioinformatics analysis.
    Yu C; Chen F; Jiang J; Zhang H; Zhou M
    Mol Med Rep; 2019 Aug; 20(2):1259-1269. PubMed ID: 31173250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.
    Makondi PT; Lee CH; Huang CY; Chu CM; Chang YJ; Wei PL
    PLoS One; 2018; 13(1):e0189582. PubMed ID: 29342159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The identification of a common different gene expression signature in patients with colorectal cancer.
    Zhao ZW; Fan XX; Yang LL; Song JJ; Fang SJ; Tu JF; Chen MJ; Zheng LY; Wu FZ; Zhang DK; Ying XH; Ji JS
    Math Biosci Eng; 2019 Apr; 16(4):2942-2958. PubMed ID: 31137244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.
    Tong M; Zheng W; Lu X; Ao L; Li X; Guan Q; Cai H; Li M; Yan H; Guo Y; Chi P; Guo Z
    Oncotarget; 2015 Dec; 6(38):41216-27. PubMed ID: 26515599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Novel miRNAs, Targeting Genes, Signaling Pathway, and the Small Molecule for Overcoming Oxaliplatin Resistance of Metastatic Colorectal Cancer.
    Misbah M; Kumar M; Lee KH; Shen SC
    Biomed Res Int; 2022; 2022():3825760. PubMed ID: 36193307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of genes involved in the four stages of colorectal cancer: Gene expression profiling.
    Shi G; Wang Y; Zhang C; Zhao Z; Sun X; Zhang S; Fan J; Zhou C; Zhang J; Zhang H; Liu J
    Mol Cell Probes; 2018 Feb; 37():39-47. PubMed ID: 29179987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Potential Key Genes and Pathways in Enzalutamide-Resistant Prostate Cancer Cell Lines: A Bioinformatics Analysis with Data from the Gene Expression Omnibus (GEO) Database.
    Zheng L; Dou X; Ma X; Qu W; Tang X
    Biomed Res Int; 2020; 2020():8341097. PubMed ID: 32724813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
    Li XX; Zheng HT; Peng JJ; Huang LY; Shi DB; Liang L; Cai SJ
    Int J Clin Exp Pathol; 2014; 7(5):2729-36. PubMed ID: 24966994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer.
    Yu C; Hong H; Lu J; Zhao X; Hu W; Zhang S; Zong Y; Mao Z; Li J; Wang M; Feng B; Sun J; Zheng M
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806905. PubMed ID: 30336768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A network-based predictive gene expression signature for recurrence risks in stage II colorectal cancer.
    Yang WJ; Wang HB; Wang WD; Bai PY; Lu HX; Sun CH; Liu ZS; Guan DK; Yang GW; Zhang GL
    Cancer Med; 2020 Jan; 9(1):179-193. PubMed ID: 31724326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.
    Allen WL; Turkington RC; Stevenson L; Carson G; Coyle VM; Hector S; Dunne P; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Aug; 11(8):1724-34. PubMed ID: 22665525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of candidate genes and miRNAs for sensitizing resistant colorectal cancer cells to oxaliplatin and irinotecan.
    Poorebrahim M; Sadeghi S; Ghanbarian M; Kalhor H; Mehrtash A; Teimoori-Toolabi L
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):153-171. PubMed ID: 31781855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of key pathways and genes in colorectal cancer using bioinformatics analysis.
    Liang B; Li C; Zhao J
    Med Oncol; 2016 Oct; 33(10):111. PubMed ID: 27581154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of key genes in colorectal cancer using random walk with restart.
    Cui X; Shen K; Xie Z; Liu T; Zhang H
    Mol Med Rep; 2017 Feb; 15(2):867-872. PubMed ID: 28000901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of hub genes, key miRNAs and potential molecular mechanisms of colorectal cancer.
    Wu S; Wu F; Jiang Z
    Oncol Rep; 2017 Oct; 38(4):2043-2050. PubMed ID: 28902367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis.
    Sun F; Liang W; Qian J
    Mol Med Rep; 2019 Oct; 20(4):3583-3596. PubMed ID: 31432188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer.
    Ruihua H; Mengyi Z; Chong Z; Meng Q; Xin M; Qiulin T; Feng B; Ming L
    Oncotarget; 2016 Dec; 7(52):87136-87146. PubMed ID: 27888624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Hub Genes and Key Pathways Associated with Anti-
    Arya KR; Bharath Chand RP; Abhinand CS; Nair AS; Oommen OV; Sudhakaran PR
    Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33803224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
    Raynal C; Pascussi JM; Leguelinel G; Breuker C; Kantar J; Lallemant B; Poujol S; Bonnans C; Joubert D; Hollande F; Lumbroso S; Brouillet JP; Evrard A
    Mol Cancer; 2010 Mar; 9():46. PubMed ID: 20196838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.